Cargando…
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Massachusetts Medical Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929374/ https://www.ncbi.nlm.nih.gov/pubmed/35263535 http://dx.doi.org/10.1056/NEJMc2201933 |
| _version_ | 1784670848975634432 |
|---|---|
| author | Takashita, Emi Kinoshita, Noriko Yamayoshi, Seiya Sakai-Tagawa, Yuko Fujisaki, Seiichiro Ito, Mutsumi Iwatsuki-Horimoto, Kiyoko Halfmann, Peter Watanabe, Shinji Maeda, Kenji Imai, Masaki Mitsuya, Hiroaki Ohmagari, Norio Takeda, Makoto Hasegawa, Hideki Kawaoka, Yoshihiro |
| author_facet | Takashita, Emi Kinoshita, Noriko Yamayoshi, Seiya Sakai-Tagawa, Yuko Fujisaki, Seiichiro Ito, Mutsumi Iwatsuki-Horimoto, Kiyoko Halfmann, Peter Watanabe, Shinji Maeda, Kenji Imai, Masaki Mitsuya, Hiroaki Ohmagari, Norio Takeda, Makoto Hasegawa, Hideki Kawaoka, Yoshihiro |
| author_sort | Takashita, Emi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8929374 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Massachusetts Medical Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89293742022-03-21 Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 Takashita, Emi Kinoshita, Noriko Yamayoshi, Seiya Sakai-Tagawa, Yuko Fujisaki, Seiichiro Ito, Mutsumi Iwatsuki-Horimoto, Kiyoko Halfmann, Peter Watanabe, Shinji Maeda, Kenji Imai, Masaki Mitsuya, Hiroaki Ohmagari, Norio Takeda, Makoto Hasegawa, Hideki Kawaoka, Yoshihiro N Engl J Med Correspondence Massachusetts Medical Society 2022-03-09 /pmc/articles/PMC8929374/ /pubmed/35263535 http://dx.doi.org/10.1056/NEJMc2201933 Text en Copyright © 2022 Massachusetts Medical Society. All rights reserved. http://www.nejmgroup.org/legal/terms-of-use.htm This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
| spellingShingle | Correspondence Takashita, Emi Kinoshita, Noriko Yamayoshi, Seiya Sakai-Tagawa, Yuko Fujisaki, Seiichiro Ito, Mutsumi Iwatsuki-Horimoto, Kiyoko Halfmann, Peter Watanabe, Shinji Maeda, Kenji Imai, Masaki Mitsuya, Hiroaki Ohmagari, Norio Takeda, Makoto Hasegawa, Hideki Kawaoka, Yoshihiro Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 |
| title | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 |
| title_full | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 |
| title_fullStr | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 |
| title_full_unstemmed | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 |
| title_short | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 |
| title_sort | efficacy of antiviral agents against the sars-cov-2 omicron subvariant ba.2 |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929374/ https://www.ncbi.nlm.nih.gov/pubmed/35263535 http://dx.doi.org/10.1056/NEJMc2201933 |
| work_keys_str_mv | AT takashitaemi efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT kinoshitanoriko efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT yamayoshiseiya efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT sakaitagawayuko efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT fujisakiseiichiro efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT itomutsumi efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT iwatsukihorimotokiyoko efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT halfmannpeter efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT watanabeshinji efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT maedakenji efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT imaimasaki efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT mitsuyahiroaki efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT ohmagarinorio efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT takedamakoto efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT hasegawahideki efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 AT kawaokayoshihiro efficacyofantiviralagentsagainstthesarscov2omicronsubvariantba2 |